Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3974169 | 1.00 | TP53 (0.33) | TP53CYP1A2GAACYP2C9PKM | |
| SCHEMBL30280302 | 1.00 | TP53 (0.33) | TP53CYP1A2GAACYP2C9PKM | |
| SCHEMBL30280181 | 1.00 | TP53 (0.33) | TP53CYP1A2GAACYP2C9PKM | |
| SCHEMBL30280242 | 0.96 | TP53 (0.31) | TP53 | |
| SCHEMBL30322778 | 0.79 | — | — | |
| SCHEMBL16243692 | 0.76 | SLC7A5 (0.33) | TP53CYP1A2GAACYP2C9PKM | |
| SCHEMBL375633 | 0.76 | TP53 (0.47) | TP53CYP1A2GAACYP2C9PKM | |
| SCHEMBL26110798 | 0.73 | TP53 (0.44) | TP53CYP1A2GAACYP2C9PKM | |
| Hydrochloric Acid SCHEMBL25174962 | 0.73 | SLC7A5 (0.41) | — | |
| Hydrochloric Acid SCHEMBL31512238 | 0.73 | SLC7A5 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376085-A1 | BENZIMIDAZOLES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2024-11-14 | — | — | US | disclosed |
| EP-4408530-A1 | BENZIMIDAZOLES AS MODULATORS OF IL-17 | Janssen Pharmaceutica NV (BE) | 2024-08-07 | — | — | EP | disclosed |
| WO-2023049888-A1 | BENZIMIDAZOLES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376085-A1 | BENZIMIDAZOLES AS MODULATORS OF IL-17 | IL17A, IL23R, IL4I1 | TP53 3063/4885CYP1A2 359/4885GAA 1860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.